S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
A gold storm is coming… (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
A gold storm is coming… (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
A gold storm is coming… (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
A gold storm is coming… (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
LON:AZN

AstraZeneca - AZN Share Forecast, Price & News

£105.78
+328.00 (+3.20%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
£102.74
▼
£105.78
50-Day Range
£102.50
▼
£118.02
52-Week Range
8,214
▼
£118.86
Volume
1.77 million shs
Average Volume
2.15 million shs
Market Capitalization
£163.91 billion
P/E Ratio
10,074.29
Dividend Yield
2.08%
Price Target
£116.94

AstraZeneca MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
10.6% Upside
£116.94 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
-2.35
Upright™ Environmental Score
News Sentiment
0.08mentions of AstraZeneca in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

See Top Rated MarketRank™ Stocks Here
AZN stock logo

About AstraZeneca (LON:AZN) Stock

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Receive AZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

AZN Stock News Headlines

February 4, 2023 | americanbankingnews.com
Berenberg Bank Reaffirms "Buy" Rating for AstraZeneca (LON:AZN)
February 3, 2023 | americanbankingnews.com
AstraZeneca (LON:AZN) PT Set at £135 by JPMorgan Chase & Co.
February 5, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
January 27, 2023 | americanbankingnews.com
AstraZeneca (LON:AZN) PT Raised to £135
December 29, 2022 | finance.yahoo.com
AstraZeneca's (AZN) Imfinzi+Imjudo Gets Japan Nod for 2 Cancers
December 27, 2022 | finance.yahoo.com
AstraZeneca PLC (LON:AZN) is a favorite amongst institutional investors who own 88%
December 23, 2022 | markets.businessinsider.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: AstraZeneca (AZN) and ContraFect (CFRX)
December 21, 2022 | finance.yahoo.com
AstraZeneca (AZN) Gets EU Nod to Expanded Use of 2 Cancer Drugs
February 5, 2023 | Wall Street Watch Dogs (Ad)
“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
November 28, 2022 | finance.yahoo.com
AstraZeneca Bets On UK Listed Firm For Lung Diseases
November 10, 2022 | finance.yahoo.com
AstraZeneca PLC (AZN) Q3 2022 Earnings Call Transcript
November 9, 2022 | finance.yahoo.com
AstraZeneca Q3 Preview: Can Shares Stay Strong?
November 4, 2022 | finance.yahoo.com
Will AstraZeneca PLC (AZN) Deliver Promising Return?
November 2, 2022 | finance.yahoo.com
Astrazeneca (AZN) Stock Moves -0.25%: What You Should Know
November 1, 2022 | finance.yahoo.com
European Regulator Grants Complete Approval To AstraZeneca's COVID-19 Vaccine
October 20, 2022 | morningstar.co.uk
TOP NEWS: AstraZeneca says Evusheld shows promise on Covid variants - Morningstar
October 18, 2022 | finance.yahoo.com
EVUSHELD™ RECEIVES HEALTH CANADA APPROVAL FOR TREATMENT OF COVID-19 - Yahoo Finance
October 14, 2022 | seekingalpha.com
AstraZeneca, Alvogen fined in South Korea over alleged stalling of generic cancer drug
October 11, 2022 | finance.yahoo.com
Illumina Inks AI Pact With AstraZeneca To Accelerate Drug Target Discovery
October 10, 2022 | bloomberg.com
AstraZeneca Nasal Spray Vaccine for Covid Fizzles in Small, Early Trial - Bloomberg
October 10, 2022 | reuters.com
AstraZeneca's COVID vaccine suffers a setback in nasal spray trial - Reuters
October 8, 2022 | msn.com
Friday Morning's Market Moves: CVS, Dexcom, Halliburton, AstraZeneca
October 7, 2022 | finance.yahoo.com
Here’s Why AstraZeneca PLC (AZN) Benefited in the Second Quarter - Yahoo Finance
October 7, 2022 | finance.yahoo.com
Here’s Why AstraZeneca PLC (AZN) Benefited in the Second Quarter
October 4, 2022 | marketwatch.com
ADRs End Higher, ABB and AstraZeneca Trade Actively - MarketWatch
October 3, 2022 | benzinga.com
Will Chart Analysts Notice Bad Omen on AstraZeneca's Chart - AstraZeneca (NASDAQ:AZN) - Benzinga
October 3, 2022 | finance.yahoo.com
Zacks.com featured highlights include Coca-Cola, General Dynamics, AstraZeneca, Boise Cascade and Insperity - Yahoo Finance
See More Headlines
Receive AZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Drug Manufacturers - Major
Sub-Industry
N/A
Sector
Medical
Current Symbol
LON:AZN
CUSIP
N/A
CIK
N/A
Web
www.astrazeneca.com
Phone
+44-20-73045000
Fax
N/A
Employees
83,100
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
£116.94
High Stock Price Forecast
£135
Low Stock Price Forecast
GBX 6,950
Forecasted Upside/Downside
+10.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
10,074.29
Forward P/E Ratio
1,760.07
P/E Growth
1.92
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
88.97
Current Ratio
0.81
Quick Ratio
0.59

Sales & Book Value

Annual Sales
£45.16 billion
Price / Sales
3.63
Cash Flow
GBX 271.99 per share
Price / Cash Flow
38.89
Book Value
GBX 2,269.60 per share
Price / Book
4.66

Miscellaneous

Outstanding Shares
1,549,528,000
Free Float
N/A
Market Cap
£163.91 billion
Optionable
Optionable
Beta
N/A

Key Executives

  • Mr. Pascal Soriot D.V.M. (Age 63)
    M.B.A., CEO & Exec. Director
    Comp: $4.75M
  • Dr. Aradhana Sarin M.D. (Age 47)
    CFO & Exec. Director
    Comp: $3.51M
  • Mr. Marc Dunoyer (Age 70)
    CEO of Alexion & Chief Strategy Officer
    Comp: $1.66M
  • Ms. Pam P. Cheng (Age 51)
    EVP of Operations & Information Technology and Member of External Sustainability Advisory Board
  • Mr. Chris Sheldon
    Head of Investor Relations
  • Mr. Jeffrey Pott
    Chief HR Officer, Gen. Counsel & Member of External Sustainability Advisory Board
  • Ms. Katarina Ageborg
    EVP of Sustainability, Chief Compliance Officer & Member of External Sustainability Advisory Board
  • Gonzalo Vina
    Head of Global Media Relations
  • Dr. Menelas Pangalos Ph.D. (Age 55)
    EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board
  • Dr. Ruud Dobber Ph.D.
    Exec. Vice-Pres of BioPharmaceuticals Bus. Unit

Key Competitors

View All Competitors













AZN Stock - Frequently Asked Questions

Should I buy or sell AstraZeneca stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AZN shares.
View AZN analyst ratings or view top-rated stocks.

What is AstraZeneca's stock price forecast for 2023?

8 Wall Street research analysts have issued 1-year price objectives for AstraZeneca's shares. Their AZN share price forecasts range from GBX 6,950 to £135. On average, they predict the company's stock price to reach £116.94 in the next twelve months. This suggests a possible upside of 10.6% from the stock's current price.
View analysts price targets for AZN or view top-rated stocks among Wall Street analysts.

How have AZN shares performed in 2023?

AstraZeneca's stock was trading at £112.18 at the start of the year. Since then, AZN stock has decreased by 5.7% and is now trading at £105.78.
View the best growth stocks for 2023 here.

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca announced a dividend on Friday, July 29th. Stockholders of record on Thursday, August 11th will be given a dividend of GBX 76.40 per share on Monday, September 12th. This represents a dividend yield of 0.7%. The ex-dividend date is Thursday, August 11th. The official announcement can be viewed at this link.
Read our dividend analysis for AZN.

Is AstraZeneca a good dividend stock?

AstraZeneca (LON:AZN) pays an annual dividend of GBX 2.83 per share and currently has a dividend yield of 2.08%. The dividend payout ratio is 269.85%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for AZN.

What other stocks do shareholders of AstraZeneca own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include GSK (GSK), NVIDIA (NVDA), Gilead Sciences (GILD), Intel (INTC), Vodafone Group Public (VOD), Advanced Micro Devices (AMD), Alibaba Group (BABA), Pfizer (PFE), QUALCOMM (QCOM) and The Hain Celestial Group (HAIN).

What is AstraZeneca's stock symbol?

AstraZeneca trades on the London Stock Exchange (LON) under the ticker symbol "AZN."

How do I buy shares of AstraZeneca?

Shares of AZN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is AstraZeneca's stock price today?

One share of AZN stock can currently be purchased for approximately £105.78.

How much money does AstraZeneca make?

AstraZeneca (LON:AZN) has a market capitalization of £163.91 billion and generates £45.16 billion in revenue each year.

How many employees does AstraZeneca have?

The company employs 83,100 workers across the globe.

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 Francis Crick Avenue Cambridge Biomedical Campus, CAMBRIDGE, CB2 0AA, United Kingdom. The official website for the company is www.astrazeneca.com. The biopharmaceutical company can be reached via phone at +44-20-73045000.

This page (LON:AZN) was last updated on 2/5/2023 by MarketBeat.com Staff